Results 171 to 180 of about 812,159 (298)

Pharmacokinetics, Effectiveness and Safety of Certolizumab Pegol in Children and Adolescents With Active Juvenile Idiopathic Arthritis: 9+‐Year Results From a Multicenter, Open‐Label Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective The purpose of this study was to assess the pharmacokinetics, effectiveness, safety, and immunogenicity of certolizumab pegol (CZP) in polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods Pediatric Arthritis Study of Certolizumab Pegol (NCT01550003), a multicenter, open‐label study, enrolled patients aged 2 to 17 years with ...
Hermine I. Brunner   +52 more
wiley   +1 more source

Anti–Carbamylated Fibrinogen Autoantibodies of IgG and IgA Isotypes Contribute to a Better Prognostic Stratification in Very Early Rheumatoid Arthritis: Data From the French National ESPOIR Cohort

open access: yesArthritis &Rheumatology, EarlyView.
Objective The aim of this study was to investigate the prevalence and longitudinal evolution of anti–carbamylated fibrinogen antibodies (ACa‐Fib) of IgG and IgA isotypes in early rheumatoid arthritis (RA) and determine whether these antibodies provide additional diagnostic and prognostic information beyond anti–cyclic citrullinated peptide (anti‐CCP ...
Pauline Brevet   +11 more
wiley   +1 more source

Navigating interstitial lung disease associated with rheumatoid arthritis (RA-ILD): from genetics to clinical landscape. [PDF]

open access: yesFront Med (Lausanne)
Bernardinello N   +6 more
europepmc   +1 more source

Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice

open access: yes, 2007
OBJECTIVE: To evaluate the effectiveness and safety of adalimumab in patients with rheumatoid arthritis (RA) who previously discontinued tumour necrosis factor (TNF) antagonists for any reason in clinical practice. METHODS: ReAct (Research in Active
BURMESTER GR   +10 more
core  

Outcomes in Progressive Pulmonary Fibrosis in Systemic Autoimmune Rheumatic Diseases: Real‐World Data From the ILD‐PRO Registry

open access: yesArthritis &Rheumatology, EarlyView.
Objective We evaluated baseline characteristics, treatment patterns, and outcomes in patients with systemic autoimmune rheumatic disease–associated progressive pulmonary fibrosis (SARD‐PPF) and evaluated whether outcomes differed by SARD subtype. Methods The ILD‐PRO Registry is a prospective multicenter US registry of patients with PPF.
Sonali J. Bracken   +7 more
wiley   +1 more source

Percutaneous coronary intervention (PCI) in patients of rheumatoid arthritis(RA): A systematic review and meta-analysis. [PDF]

open access: yesIndian Heart J
Piplani S   +15 more
europepmc   +1 more source

Updated COVID‐19 Vaccines and Health Outcomes in Patients With Autoimmune Rheumatic Conditions

open access: yesArthritis &Rheumatology, EarlyView.
Objective We aimed to assess the association between COVID‐19 vaccination status and COVID‐19‐related hospital admissions, need for mechanical ventilation or extracorporeal membrane oxygenation (ECMO), and death in people with autoimmune rheumatic conditions. Methods We conducted a retrospective cohort study using National Clinical Cohort Collaborative
Lesley E. Jackson   +127 more
wiley   +1 more source

Home - About - Disclaimer - Privacy